Nivolumab (Opdivo®) is a monoclonal antibody. It binds to the PD-1 receptor, thereby blocking the interaction of the PD-1 receptor with PD-L1 and PD-L2. Immunosuppressive responses mediated by the PD-1 pathway will be blocked (such as tumor immune responses). Nivolumab can be used to treat a variety of malignant tumors in adults. Nivolumab is commonly used in the form...
